Literature DB >> 1913467

An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression.

G Barosi1, A Buratti, A Costa, L N Liberato, C Balduini, M Cazzola, V Rosti, U Magrini, E Ascari.   

Abstract

Among 761 consecutive patients with chronic myeloproliferative disorders (CMD), it was found that 18 (nine men and nine women) did not fulfill at presentation the established diagnostic criteria for the typical forms. In seven patients, the diagnosis of CMD was made on the basis of an intense and persistent thrombocytosis that complicated splenectomy. The other 11 patients had various combinations of the following signs suggesting CMD: splenomegaly, bone marrow myeloid hyperplasia and/or slight myelofibrosis, mild thrombocytosis and/or leukocytosis, and rare immature myeloid cells in the peripheral blood. All patients were younger than 46 years of age (median age, 31.5 years; range, 20 to 45 years). A major thrombotic event was the most frequent presenting feature (eight of 18 cases), and thrombotic complications supervened in seven of the eight splenectomized patients (six in the portal system), raising the overall rate of patients with thrombotic events in their history to 11 of 18. At a median follow-up of 50 months (range, 24 to 241 months), three patients had died of thrombotic complications (two after splenectomy). The 15 surviving patients had stable disease, and 12 of them were not receiving cytoreductive therapy. Spontaneous growth of circulating burst-forming units erythroid was demonstrated in one patient, and erythroid responsiveness to erythropoietin appeared higher than in the normal controls in four. Spontaneous in vitro platelet aggregation in whole blood and/or platelet-rich plasma was seen in five of seven patients. It was concluded that a difficult to identify, slowly progressive form of CMD occurs in young people, that it carries a high risk of thrombosis, and that splenectomy is a high risk procedure in these cases.

Entities:  

Mesh:

Year:  1991        PMID: 1913467     DOI: 10.1002/1097-0142(19911115)68:10<2310::aid-cncr2820681034>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Budd-Chiari syndrome following laparoscopic cholecystectomy.

Authors:  Pooja D Amarapurkar; Sunil J Parekh; Punamiya Sundeep; Deepak N Amarapurkar
Journal:  J Clin Exp Hepatol       Date:  2013-07-31

2.  Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Authors:  Hans Carl Hasselbalch
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

3.  Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Elisa Bonetti; Rita Campanelli; Adriana Carolei; Paolo Catarsi; Antonina M Isgrò; Letizia Lupo; Margherita Massa; Valentina Poletto; Gianluca Viarengo; Laura Villani; Umberto Magrini
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

4.  High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis.

Authors:  Vittorio Rosti; Elisa Bonetti; Gaetano Bergamaschi; Rita Campanelli; Paola Guglielmelli; Marcello Maestri; Umberto Magrini; Margherita Massa; Carmine Tinelli; Gianluca Viarengo; Laura Villani; Massimo Primignani; Alessandro M Vannucchi; Francesco Frassoni; Giovanni Barosi
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

Review 5.  Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: Need for a new classification.

Authors:  Zeeshan A Wani; Riyaz A Bhat; Ajeet S Bhadoria; Rakhi Maiwall
Journal:  Saudi J Gastroenterol       Date:  2015 May-Jun       Impact factor: 2.485

Review 6.  Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-06-26       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.